Liquidia (NASDAQ:LQDA) CAO Dana Boyle Sells 5,892 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 5,892 shares of the stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $167,804.16. Following the completion of the transaction, the chief accounting officer directly owned 165,609 shares in the company, valued at approximately $4,716,544.32. This represents a 3.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, July 27th, Dana Boyle sold 1,600 shares of Liquidia stock. The stock was sold at an average price of $87.53, for a total value of $140,048.00.

Liquidia Stock Performance

Shares of Liquidia stock traded down $0.86 on Tuesday, hitting $26.81. The stock had a trading volume of 3,092,611 shares, compared to its average volume of 5,078,983. Liquidia Corporation has a twelve month low of $21.94 and a twelve month high of $93.61. The business’s 50 day moving average is $63.40 and its two-hundred day moving average is $61.76. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of 19.57 and a beta of 0.61.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The firm had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business’s revenue for the quarter was up 1842.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.49) earnings per share. Analysts forecast that Liquidia Corporation will post 2.05 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on LQDA. Bank of America increased their price objective on Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Raymond James Financial reissued an “outperform” rating on shares of Liquidia in a research report on Thursday, October 8th. Weiss Ratings upgraded shares of Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Piper Sandler set a $129.00 price target on shares of Liquidia in a research report on Friday, July 24th. Finally, Citigroup reiterated a “neutral” rating on shares of Liquidia in a research note on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Liquidia presently has a consensus rating of “Hold” and a consensus price target of $83.69.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Institutional Investors Weigh In On Liquidia

Several institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE grew its position in Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after buying an additional 360,372 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Liquidia during the 2nd quarter worth $29,694,000. Eversept Partners LP increased its stake in Liquidia by 33.0% during the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after acquiring an additional 167,949 shares during the period. Seven Fleet Capital Management LP raised its holdings in Liquidia by 25.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after acquiring an additional 51,727 shares in the last quarter. Finally, Pale Fire Capital SE raised its holdings in Liquidia by 2.4% in the 1st quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock valued at $14,657,000 after acquiring an additional 8,985 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).